The Rationale for Investigating DNA-PK as a Target in Prostate Cancer

Video

Karen E. Knudsen, PhD, discusses the rationale for investigating DNA-dependent protein kinase as a target in prostate cancer.

Karen E. Knudsen, PhD, chair and Hilary Koprowski Professor, Department of Cancer Biology, professor of cancer biology, urology, medical oncology, and radiation oncology, and enterprise director, Sidney Kimmel Cancer Center, Thomas Jefferson University Hospital, discusses the rationale for investigating DNA-dependent protein kinase (DNA-PK) as a target in prostate cancer.

DNA-PK gene encoding alterations have the potential to inform which patients have indolent versus metastatic prostate cancer, explains Knudsen.

In other tumor types, variants of DNA-PK suggest are strongly associated with disease development and aggressive disease, says Knudsen. Additionally, some data suggest that DNA-PK alterations are particularly significant in African American women.

As DNA-PK has not been widely investigated in prostate cancer, research efforts are needed to determine its role in the space.

Related Videos
Saad Z. Usmani, MD, MBA, FACP, FASCO
Rebecca Kristeleit, BSc, MBChB, MRCP, PhD
Don S. Dizon, MD
Rohan Garje, MD
Sarah E. S. Leary, MD, MS, attending physician, medical director, Pediatric Brain Tumor Program, Seattle Children’s Hospital; professor, Department of Pediatrics, University of Washington School of Medicine
Samer A. Srour, MB ChB, MS
Rita Nanda, MD
Vikram Narayan, MD
Daniel Olson, MD
Vishal Patel, MD, FAAD, FACMS, associate professor, Dermatology, George Washington (GW) School of Medicine & Health Sciences